Immuneering (IMRX) Research & Development: 2020-2023
Historic Research & Development for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $11.9 million.
- Immuneering's Research & Development rose 20.65% to $11.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $41.6 million, marking a year-over-year increase of 14.75%. This contributed to the annual value of $41.6 million for FY2023, which is 14.77% up from last year.
- According to the latest figures from Q4 2023, Immuneering's Research & Development is $11.9 million, which was up 18.51% from $10.1 million recorded in Q3 2023.
- In the past 5 years, Immuneering's Research & Development ranged from a high of $11.9 million in Q4 2023 and a low of $2.8 million during Q2 2020.
- Over the past 3 years, Immuneering's median Research & Development value was $9.2 million (recorded in 2022), while the average stood at $8.7 million.
- Data for Immuneering's Research & Development shows a peak YoY spiked of 147.66% (in 2021) over the last 5 years.
- Over the past 4 years, Immuneering's Research & Development (Quarterly) stood at $4.9 million in 2020, then spiked by 62.57% to $8.0 million in 2021, then climbed by 24.17% to $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023.
- Its Research & Development was $11.9 million in Q4 2023, compared to $10.1 million in Q3 2023 and $9.5 million in Q2 2023.